Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2015)
13 slides from Resonance Health's shareholder meeting presentation, Nov 20, 2015
Slide 1: Resonance Health Limited Annual General Meeting
ASX: RHT For personal use only Resonance Health Limited ASX: RHT Annual General Meeting 20th November 2015
Slide 2: AGM Presentation
AGM Presentation ___________________________________________________________________________________________ For personal use only • Company Financial Summary • Products: – Year in review and strategy • New Opportunities • Overall Summary
Slide 3: Resonance Health Limited
Resonance Health Limited ___________________________________________________________________________________________ • RHT specialises in the development and For personal use only delivery of non-invasive quantitative medical imaging software and services • Market capitalisation ~ AU$ 12.5 million (
Slide 4: Year in Review
Year in Review ___________________________________________________________________________________________ 24 new sites established & 14% increase in sales For personal use only receipts across FerriScan and cardiac T2* 29% increase in sales volumes for routine clinical use in UK market and sign
Slide 5: Year in Review: FerriScan
Year in Review: FerriScan ___________________________________________________________________________________________ • Routine clinical use growing For personal use only – Completed 30,000+ FerriScans since on market – Several UK and Canadian customers have completed 1,000+ • Continued use in pharm
Slide 6: FerriScan: Strategy
FerriScan: Strategy _______________________________________________________________________________________________ • Grow revenue in targeted markets For personal use only – Provide solid income base to grow the Company and develop new products for larger opportunities – Increase marketing efforts;
Slide 7: FerriScan: Strategy
FerriScan: Strategy _______________________________________________________________________________________________ For personal use only 1) Sickle Cell Disease (USA) ~ 70,000 patients with SCD in USA1 (~15,000 transfused) ~ 1,000 babies born in USA with SCD each year - Paediatric hospitals provide
Slide 8: Review & Strategy: HepaFat-Scan
Review & Strategy: HepaFat-Scan ___________________________________________________________________________________________ • Winner of 2014 WA Innovator of the Year award For personal use only • Studies to generate data and publications that will enhance acceptance and uptake in clinical community
Slide 9: Review & Strategy: Fibrosis Measurement
Review & Strategy: Fibrosis Measurement _______________________________________________________________________________________________ • Two Prototypes Developed: For personal use only - Screening test to detect whether liver is normal or has fibrosis - Test to distinguish between low and high fibr
Slide 10: HepaFat-Scan & Fibrosis Measurement
HepaFat-Scan & Fibrosis Measurement _______________________________________________________________________________________________ For personal use only Potential Market (USA) Total population: ~320 million 30% fatty liver disease1: ~96 million 3-5% develop NASH: ~3-5 million (assume 4 million) 4 m
Slide 11: New R&D
New R&D _______________________________________________________________________________________________ For personal use only Develop and Grow Company: 1) Add value to existing products 2) Diversify: add new products to portfolio Add Value: - Combine FerriScan with a fibrosis measurement - Bone marr
Slide 12: Summary & Overall Strategy
Summary & Overall Strategy _______________________________________________________________________________________________ • Profitable FY 14/15, cash on hand For personal use only • Focus on growth and development of Company • FerriScan: Niche product – Potential to grow (SCD & new markets) – Reven
Slide 13: End of Presentation
For personal use only End of Presentation
Resonance Health — Shareholder Meeting (November 2015) on 6ix